Ключевые слова:
Apixaban; Dabigatran; Direct oral anticoagulants; Edoxaban; Personalized approach; Pharmacogenetics; Pharmacokinetics; Rivaroxaban
anticoagulant agent; dabigatran; pyrazole derivative; pyridone derivative; rivaroxaban; atrial fibrillation; cerebrovascular accident; human; oral drug administration; personalized medicine; treatment outcome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Precision Medicine; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Treatment Outcome
Скрипка А. И. Алена Игоревна 1992-
Когай В. В.
Листратов А. И. Александр Иванович 1996-
Соколова А. А. Анастасия Андреевна 1983-
Напалков Д. А. Дмитрий Александрович 1975-
Фомин В. В. Виктор Викторович 1978-
Skripka A. I. Alena Igorevna 1992-
Kogay V. V.
Listratov A. I. Aleksandr Ivanovich 1996-
Sokolova A. A. Anastasiya Andreevna 1983-
Napalkov D. A. Dmitrij Aleksandrovich 1975-
Fomin V. V. Viktor Viktorovich 1978-
Personalized approach for direct oral anticoagulant prescription: From theory to practice [Персонализированный подход к назначению прямых оральных антикоагулянтов: от теории к практике]
Personalized approach for direct oral anticoagulant prescription: From theory to practice [Персонализированный подход к назначению прямых оральных...
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 91, Вып. 7 С. 111-120
2019
Статья
Apixaban Dabigatran Direct oral anticoagulants Edoxaban Personalized approach Pharmacogenetics Pharmacokinetics Rivaroxaban
anticoagulant agent dabigatran pyrazole derivative pyridone derivative rivaroxaban atrial fibrillation cerebrovascular accident human oral drug administration personalized medicine treatment outcome Administration, Oral Anticoagulants Atrial Fibrillation Dabigatran Humans Precision Medicine Pyrazoles Pyridones Rivaroxaban Stroke Treatment Outcome
Data on possibilities of personalized approach for direct oral anticoagulants (DOAC) choice in patients with atrial fibrillation are presented in the article. We also review clinical and fundamental studies and future perspectives on pharmacogenetic and pharmacokinetic tests to predict the efficacy and safety of DOAC. © 2019 Consilium Medikum. All rights reserved.